Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Retinal Pigment Epithelial Detachment Clinical Trial

Official title:

A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00749021
• Other study ID #: FVF4332s
• Status: Completed
• Phase: Phase 1
• First received: September 8, 2008
• Last updated: October 3, 2012
• Start date: September 2008
• Est. completion date: August 2012

Study information

• Verified date: October 2012
• Source: Southern California Desert Retina Consultants, MC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Patient is 50 years or older

• Patient is willing to participate in this study and to follow the criteria and protocol of this study.

• Patient is not involved with another clinical trial.

• Ability to understand the informed consent and willingness to sign the consent.

• Presence of a submacular vascularized or fibrovascular PED. Central foveal involvement by the PED or the CNV due to age related macular degeneration.

• PED less than or equal to 12 disc area in size

• BCVA with ETDRS of greater than or equal to 19 letters and less than or equal to 69 letters (20/400 to 20/40)

• Central 1-mm foveal thickness of greater than or equal to 250 microns on OCT.

• Greatest linear diameter of the submacular hemorrhage needs to be less than 50% of the entire PED.

• Submacular fibrosis needs to be less than 50% of the entire PED.

• Sufficiently clear media (cornea, anterior chamber, lens, vitreous) for OCT, FA, and FP.

• Intraocular pressure of 25 mm or less in the study eye, with or without use of ocular hypotensive agents.

Exclusion Criteria:

• Pregnancy or lactation

• Premenopausal women not using adequate contraception

• Known serious allergies to ranibizumab, fluorescein dye, drug for pupillary dilation, topical anesthetic, sterilizing solution

• Contraindication to pupillary dilation in study eye

• Any condition (including inability to read visual acuity charts or language barrier) that may preclude patient's ability to comply with the study protocol requirements

• Presence of any advanced systemic condition or endstage disease, advanced Alzheimer syndrome, endstage cancer, etc., which will likely prevent patient from completing study.

• Previous therapeutic radiation in the region of the study eye.

• Prior anti-vascular endothelial factor therapy within 30 days.

• More than 3 sessions of prior anti-VEGF therapy.

• More than 1 prior photodynamic therapy (PDT)

• Prior triamcinolone in the past 6 months or dexamethasone in the past 1 month.

• Prior retinal pigment epithelial (RPE) tear in study eye.

• Prior ocular surgery (except YAG laser capsulotomy) for study eye within past 90 days.

• Anticipated ocular surgery (except YAG laser capsulotomy) for the next 12 months.

• Prior therapy for AMD (except minerals and vitamins), including laser, within the past 30 days.

• Prior intraocular or periocular corticosteroid therapy within the past 120 days

• Prior vitrectomy

• Presence of any causes of CNV and PED other than due to AMD.

• Presence of any substantial ocular disease (other than CNV and PED) that may compromise vision in the study eye and/or confound interpretation of the date; e.g. substantial cataracts, concomitant diabetic retinopathy affecting the macula, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked macular atrophy, ocular vascular occlusion, history of retinal detachment, uveitis, viral or other forms of chorioretinitis, etc.

• Presence of ocular disease other than AMD affecting study eye, i.e. presumed ocular histoplasmosis syndrome, angioid streaks, pathologic myopia (spherical equivalent of greater than or equal to -8 diopters of myopia or axial length of greater than or equal to 25 mm), choroidal rupture, multifocal choroiditis, etc.

• Active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at screening or Day 0.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Choroidal Neovascularization
• Retinal Detachment
• Retinal Pigment Epithelial Detachment

Intervention

Drug:
• Ranibizumab
0.5 mg of intravitreal ranibizumab monthly for 12 months
• Ranibizumab
0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
• Ranibizumab
2.0mg of intravitreal ranibizumab monthly for 12 months
• Ranibizumab
2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing

Locations

Country	Name	City	State
United States	Jules Stein Eye Institute	Los Angeles	California
United States	Southern California Desert Retina Consultants	Palm Desert	California
United States	Black Hills Regional Eye Institute	Rapid City	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Clement K. Chan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in Best Corrected Visual Acuity from baseline measured at 4 meters on the ETDRS chart at 12 months.		12 months	No
Secondary	Proportion of eyes reaching BCVA greater than or equal to 20/200		12 months	No
Secondary	Proportion of eyes gaining greater than or equal to 0, 5, 10, and 15 letters on the ETDRS chart		12 months	No
Secondary	Reduction in central macular thickness from baseline (central 1-mm subfield) as measured by an OCT		12 months	No
Secondary	Changes in choroidal neovascular lesion (CNV)size on fluorescein angiography and fundus photography from baseline		12 months	No
Secondary	Changes in retinal pigment epithelial detachment size on fluorescein angiography and fundus photography, including height of the PED and associated submacular fluid on OCT in comparison to baseline		12 months	No
Secondary	Status of fluorescein staining or leakage (increased or decreased) from baseline		12 months	No
Secondary	Ocular safety outcome including ocular complication, i.e. RPE tears, uveitis, endophthalmitis		12 months	Yes
Secondary	Systemic safety outcome including cardiovascular event, cerebral vascular events		12 months	Yes
Secondary	Proportion of patients with an improvement from baseline in Contrast Sensitivity at 24 and 48 weeks		24 and 48 weeks	No
Secondary	Proportion of patients with an improvement from baseline in the VFQ overall composite score and near and distance activities subscales at 24 and 48 weeks		24 and 48 weeks	No